热门资讯> 正文

Intelligence Therapeutics以折扣价定价1.8亿美元股票发行

2026-04-29 20:50

Intellia Therapeutics (NTLA) on Wednesday said it priced an underwritten public offering of 16.74M shares at $10.75 each, for expected gross proceeds of about $180M.
Shares down -11% in premarket. The stock closed at $13.2 on Tuesday.
The company is selling all shares in the offering. It also granted underwriters a 30-day option to purchase up to an additional 2.51M shares at the same price, less discounts and commissions.
Jefferies, Goldman Sachs, and Citigroup are acting as joint book-running managers.

More on Intellia Therapeutics

Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema - Slideshow
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Intellia Therapeutics launches $150M public stock offering
Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。